Clinical efficacy and safety of alpha-lipoic acid combined with mosapride in treatment of diabetic gastroparesis

Efficacy and safety of oral alpha-lipoic acid supplementation for type 2 diabetes management: a systematic review and dose–response meta-analysis of randomized trials

“…Table 2 summarizes the general characteristics of 16 studies [15,[35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] with 1035 participants included in this dose-response meta-analysis. In brief, the included RCTs had parallel designs and were published from March 1997 to October 2020.…”

“…Only one study implemented calorie restriction [43] and programmed physical activity [36] alongside ALA supplementation. The daily doses of oral ALA ranged from 200 mg/d [40] to 1200 mg/d [36,43]. The duration of diabetes ranged from 2 [37,42] to over 20 [46] years.…”

“…No study reported on the change of medication during the intervention period. Meanwhile, six studies [36,40,42,43,48,50] reported minor adverse events including anorexia, diarrhea, heart burn, and other gastrointestinal problems.…”

“…-19.18 mg/dL; 95% CI -38.19 to -0.17, p=0.05) (Supplementary Figure 10). The association with ALA was driven by six studies [36,37,39,40,44,46] and did not persist when these studies were excluded (Supplementary Table 18). Subgroup analysis did not show credible differences between groups Supplementary Table 19.…”

“…In the study above, in terms of serious adverse events, three including one gastric cancer in the ALA group and two duodenitis in the placebo group were observed. Al-Saber and colleagues [40] reported diverse adverse events with the most frequently reported events being mild to moderate gastrointestinal. Again, one patient in each group selfreported a mild event of hypoglycemia, judged by the investigator to be not related to ALA intake.…”